Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
NCT ID: NCT05224492
Last Updated: 2022-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
20 participants
INTERVENTIONAL
2022-02-21
2022-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
NCT03570918
Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol
NCT03517358
Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals
NCT01286259
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
NCT00000692
Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults
NCT01046682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sulforaphane Group
Sulforaphane
40 mg of Sulforaphane powder once daily.
Placebo Group
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sulforaphane
40 mg of Sulforaphane powder once daily.
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI increase of 10% or more since initiation of HIV treatment over a year period.
* BMI equal to or greater than 30.
* 18-85 years of age.
Exclusion Criteria
* Pregnancy or breastfeeding
* Intolerance to cruciferous vegetables
* Intolerance to sulforaphane
* Gluten Intolerance
* Creatinine \> 1.3 mg/dL
* GFR \< 60
* AST or ALT \> 1.5 times upper limit of normal.
* White cell count \< 2000 cells per ml.
* Hemoglobin \< 10.5 g/dL.
* Platelet count \< 140,000 per ml.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunshine Specialty Health Care
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose A. Giron, MD
Role: PRINCIPAL_INVESTIGATOR
Sunshine Specialty Health Care
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSHC1001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.